Virtual Conference
Heart 2022 Conference

M Jyotsna


Title: Effect of COVID 19 on interventional cardiology


COVID-19 pandemic has potential consequences on cardiovascular system. Many patients with COVID-19 had cardiac involvement in the form of myocardial ischemia or infarction, cardiac failure, venous thromboembolism and arterial thrombosis. Hence, we wanted to study whether it results in usage of longer stents in view of higher prevalence of thrombotic events.
Objective:  To compare the length of stents used in patients presented with acute coronary syndrome (ACS) in this pandemic era with patients presented during pre-pandemic era (Jan-April 2019).
Methods: In this cross-sectional study, we enrolled patients of ACS from January-April in 2022 and compared with patients of ACS from January to April in 2019. All these patients undergone early angioplasty (within 72 hrs of ACS presentation). We excluded the primary angioplasty patients. We included age group of patients between 18 to 80 yrs.  
Results: In pre-COVID group 227 patients and in post-COVID group 114 eligible patients were included for this study. We observed that in post-COVID group patients presented with ACS at an earlier age with mean age of 54.5± 12.2 years compared to mean age of 57± 11.3 years in pre-COVID group (P =0.07). 70.1% males in post COVID group, 72.2% males in pre COVID group. In post-COVID group 49 patients (43%) had diabetes, 57 patients (50%) had hypertension and 66 patients (57.9%) had Left ventricular dysfunction (LVD), whereas in pre-COVID group 105 patients (46.3%) had diabetes, 100 patients (44.1%) had hypertension and 142 patients (62.5%) had LVD. Risk factors and LV function were comparable between both groups (Diabetes – 50% vs 46.3%, p=0.57; Hypertension – 57.9% vs 44.1%, p=0.3; LVD – 57.9% vs 62.5%, p=0.41).  Even though overall LVD is same in both groups, post COVID group has more severe LVD percentage wise, which also not statistically different (35.1% vs 31.7%, p= 0.543). The mean stent length in post-COVID group is 37.56±18.1mm compared to mean length of 35.75±18.3mm in pre-COVID group (p=0.35). Stent length not differed between both groups with mild, moderate and severe LVD (p=0.78, 0.74, 0.51 respectively).  
Conclusion: No change in stent length in pre and post-COVID (P = 0.35), but there is a tendency for ACS occurrence in younger population in post-COVID group (p=0.07). Though moderate & severe LV dysfunction more in post-COVID group (p=0.543), difference in stent length not significant with respect to mild, moderate and severe LV dysfunction in both groups (p=0.78, 0.74,0.51).


Chief Editor of IJCDW, President of WINCARS, HOD & Professor of Cardiology, NIMS, INDIA